What's Happening?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of their Phase III clinical study, OptiTROP-Lung05, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study evaluated the efficacy of sacituzumab
tirumotecan (sac-TMT) in combination with pembrolizumab (KEYTRUDA®) as a first-line treatment for non-small cell lung cancer (NSCLC) with a PD-L1 Tumor Proportion Score of 1% or higher. The study involved 413 patients and demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to pembrolizumab alone. The combination therapy showed a median PFS that was not reached, compared to 5.7 months for pembrolizumab alone, and a 12-month PFS rate of 62.4% versus 29.0%. The study also reported a positive trend in OS, with a 12-month OS rate of 80.4% versus 68.9%. The safety profile of the combination was manageable, with no new safety signals identified.
Why It's Important?
The results of the OptiTROP-Lung05 study are significant as they suggest a new potential treatment option for patients with advanced NSCLC, a condition with limited effective therapies. The combination of sac-TMT and pembrolizumab could offer improved survival outcomes for patients, particularly those with PD-L1 positive tumors. This development is crucial for the oncology field, as it supports the use of antibody-drug conjugates (ADCs) in combination with immunotherapy, potentially setting a new standard for first-line treatment in this patient population. The study's findings, published in The Lancet, highlight the clinical and academic value of this approach, which could influence future treatment guidelines and improve patient outcomes.
What's Next?
Following the promising results of the OptiTROP-Lung05 study, Kelun-Biotech is likely to pursue regulatory approval for the combination therapy as a first-line treatment for NSCLC. The company has already initiated several registrational clinical studies in China, and Merck & Co., Inc. is conducting global Phase III trials to further evaluate the efficacy of sac-TMT in various cancer types. If approved, this therapy could become a new standard of care for NSCLC, offering a new option for patients who have limited treatment choices. The ongoing research and potential approval processes will be closely watched by the medical community and could lead to broader applications of ADCs in oncology.
